Correction to: Metabolic Brain Disease (2022) 37:1057–1070
The Fig. 4, Fig. 5, Fig. 6, Fig.7 and Fig. 8 in the article were not the final version, the final version Fig. 4, Fig. 5, Fig. 6, Fig.7 and Fig. 8 are shown below.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article can be found online at https://doi.org/10.1007/s11011-022-00937-2
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
He, Zq., Huan, Pf., Wang, L. et al. Correction to: Paeoniforin ameliorates cognitive impairment in Parkinson’s disease via JNK/p53 signaling. Metab Brain Dis 39, 255–261 (2024). https://doi.org/10.1007/s11011-023-01300-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-023-01300-9